

## References

### S-209

1. InterQual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. Aoki K, Ishikawa T, Ishiyama K, et al. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. *Br J Haematol*. 2015; 168(3): 463-466.
3. Basquiera A, Rivas M, Remaggi G, et al. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO). *Hematology*. 2016; 21(3): 162-169.
4. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia*. 2015;29(11):2126-2133.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, Version 3.2019.
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 2.2020.
7. Artz AS, Logan B, Zhu X, et al. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. *Haematologica*. 2016; 101(11):1426-1433.
8. Yew PY, Alachkar H, Yamaguchi R, et al. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplantation*. 2015; 50(9):1227-1234.
9. Koenecke C, Göhring G, de Wreede LC, et al. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. *Haematologica*. 2015; 100(3):400–408.
10. Basquiera AL, Pizzi S, Correas AG, et al. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: A multicenter experience from Argentina. *Pediatr Blood Cancer*. 2015; 62(1):153-7.
11. Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of

- the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Br J Haematol*. 2015; 171(2); 239-246.
12. Pohlen M, Groth C, Sauer T, et al. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (>60 years). *Bone Marrow Transplant*. 2016; 51(11); 1441-1448.
  13. Heidenreich S, Ziagkos D, de Wreede LC, et al. Allogeneic stem cell transplantation for patients age  $\geq 70$  years with myelodysplastic syndrome: A retrospective study of the MDS subcommittee of the chronic malignancies working party of the EBMT. *Biol Blood Marrow Transplant*. 2017; 23(1):44-52.
  14. Kröger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. *Blood*. 2015; 125(21):3347–3364.
  15. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015; 21(11):1863–1869.
  16. Beelen DW, Trensche R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. *Lancet Haematol*. 2020;7(1):e28-e39.
  17. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. *J Clin Oncol*. 2017;35(11):1154-1161.
  18. Kröger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase iii study of the EBMT (RICMAC Trial). *J Clin Oncol*. 2017;35(19):2157-2164.